Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid x receptor modulators: Development of a highly potent partial farnesoid x receptor agonist

Journal of Medicinal Chemistry

Volumn 57, Issue 19, 2014, Pages 8035-8055

  Merk, Daniel ^a   Lamers, Christina ^a   Ahmad, Khalil ^a   Carrasco Gomez, Roberto ^a   Schneider, Gisbert ^b   Steinhilber, Dieter ^a   Schubert Zsilavecz, Manfred ^a  

^a GOETHE UNIVERSITY   (Germany)

^b ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 5 [2 [4 (TRIFLUOROMETHYL)BENZAMIDO]BENZAMIDO]BENZOIC ACID; 2 [3 [2 [4 (TERT BUTYL)BENZAMIDO]BENZAMIDO]PHENYL] 4 METHYLBENZOIC ACID; 2 [3 [2 [4 (TERT BUTYL)BENZAMIDO]BENZAMIDO]PHENYL]ACETIC ACID; 2 [3 [2 [4 (TERT BUTYL)BENZAMIDO]BENZAMIDO]PHENYL]PROPANOIC ACID; 2 [4 (TERT BUTYL)BENZAMIDO] N (3 CARBAMOYLPHENYL)BENZAMIDE; 2 [4 (TERT BUTYL)BENZAMIDO] N (3 CYANOPHENYL)BENZAMIDE; 2 [4 (TERT BUTYL)BENZAMIDO] N (3 METHOXYPHENYL)BENZAMIDE; 2 [4 (TERT BUTYL)BENZAMIDO] N (3,4 DIMETHOXYPHENYL)BENZAMIDE; 2 [4 (TERT BUTYL)BENZAMIDO] N (3,4,5 TRIMETHOXYPHENYL)BENZAMIDE; 2 [4 (TERT BUTYL)BENZAMIDO] N [3 (METHYLTHIO)PHENYL]BENZAMIDE; 3 (2 CINNAMAMIDOBENZAMIDO)BENZOIC ACID; 3 [2 (2 PHENYLACETAMIDO)BENZAMIDO]BENZOIC ACID; 3 [2 (2,3 DIHYDROBENZO[B][1,4]DIOXINE 6 CARBOXAMIDO)BENZAMIDO]BENZOIC ACID; 3 [2 (4 BROMOBENZAMIDO)BENZAMIDO]BENZOIC ACID; 3 [2 (BENZO[D][1,3]DIOXOLE 5 CARBOXAMIDO)BENZAMIDO]BENZOIC ACID; 3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; 3 [2 [3 FLUORO 4 (TRIFLUOROMETHYL)BENZAMIDO]BENZAMIDO]BENZOIC ACID; 3 [2 [3,5 BIS(TRIFLUOROMETHYL)BENZAMIDO]BENZAMIDO]BENZOIC ACID; 3 [2 [4 (TERT BUTYL)BENZAMIDO]BENZAMIDO]BENZOIC ACID; 3 [[2 [[4 (TERT BUTYL)PHENYL]CARBAMOYL]PHENYL]CARBAMOYL]BENZOIC ACID; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AMIDE; ANTHRANILIC ACID DERIVATIVE; FARNESOID X RECEPTOR; FARNESOID X RECEPTOR AGONIST; MESSENGER RNA; N (3 ACETYLPHENYL) 2 [4 (TERT BUTYL)BENZAMIDO]BENZAMIDE; PARTIAL AGONIST; TETRAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTHRANILIC ACID; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR;

ACUTE TOXICITY; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; EC50; HELA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; LIVER MICROSOME METABOLISM; MOLECULAR DOCKING; NONHUMAN; RAT; REPORTER GENE; STRUCTURE ACTIVITY RELATION; TRANSACTIVATION ASSAY; AGONISTS; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; HEPG2 CELL LINE; SPRAGUE DAWLEY RAT; SYNTHESIS;

ANIMALS; DRUG DISCOVERY; HEP G2 CELLS; HUMANS; MOLECULAR DOCKING SIMULATION; ORTHO-AMINOBENZOATES; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84907895561     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500937v     Document Type: Article

References (46)

1. Fiorucci, S.; Mencarelli, A.; Distrutti, E.; Palladino, G.; Cipriani, S. Targeting farnesoid-X-receptor: from medicinal chemistry to disease treatment Curr. Med. Chem. 2010, 2, 139-159
2. Fiorucci, S.; Mencarelli, A.; Distrutti, E.; Zampella, A. Farnesoid X receptor: from medicinal chemistry to clinical applications Future Med. Chem. 2012, 7, 877-891
3. Düfer, M.; Horth, K.; Wagner, R.; Schittenhelm, B.; Prowald, S.; Wagner, T.; Oberwinkler, J.; Lukowski, R.; Gonzalez, F.; Krippeit-Drews, P.; Drews, G. Bile Acids Acutely Stimulate Insulin Secretion of Mouse-Cells via Farnesoid X Receptor Activation and KATP Channel Inhibition Diabetes 2012, 6, 1479-1489
4. Düfer, M.; Hörth, K.; Krippeit-Drews, P.; Drews, G. The significance of the nuclear farnesoid X receptor (FXR) in cell function Islets 2012, 5, 333-338
5. Li, Y.; Jadhav, K.; Zhang, Y. Bile acid receptors in non-alcoholic fatty liver disease Biochem. Pharmacol. 2013, 11, 1517-1524
6. Adorini, L.; Pruzanski, M.; Shapiro, D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis Drug Discovery Today 2012, 17-18, 988-997
7. Musso, G.; Gambino, R.; Cassader, M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis Prog. Lipid Res. 2013, 1, 175-191
8. Renga, B.; Mencarelli, A.; Vavassori, P.; Brancaleone, V.; Fiorucci, S. The bile acid sensor FXR regulates insulin transcription and secretion Biochim. Biophys. Acta 2010, 3, 363-372
9. Wang, X.; Fu, X.; van Ness, C.; Meng, Z.; Ma, X.; Huang, W. Bile Acid Receptors and Liver Cancer Curr. Pathobiol. Rep. 2013, 1, 29-35
10. Nijmeijer, R. M.; Gadaleta, R. M.; van Mil, S. W. C.; van Bodegraven, A. A.; Crusius, J. B.; Dijkstra, G.; Hommes, D. W.; de Jong, D. J.; Stokkers, P. C.; Verspaget, H. W.; Weersma, R. K.; van der Woude, C. J.; Stapelbroek, J. M.; Schipper, M. E.; Wijmenga, C.; van Erpecum, K. J.; Oldenburg, B. Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease PLoS One 2011, 8, e23745
11. Hollman, D. A. A.; Milona, A.; van Erpecum, K. J.; van Mil, S. W. C. Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms Biochim. Biophys. Acta 2012, 11, 1443-1452
12. Wildenberg, M. E.; van den Brink, G. R. FXR activation inhibits inflammation and preserves the intestinal barrier in IBD Gut 2011, 4, 432-433
13. Hageman, J.; Herrema, H.; Groen, A. K.; Kuipers, F. A role of the bile salt receptor FXR in atherosclerosis Arterioscler. Thromb. Vasc. Biol. 2010, 8, 1519-1528
14. Mencarelli, A.; Fiorucci, S. FXR an emerging therapeutic target for the treatment of atherosclerosis J. Cell. Mol. Med. 2010, 1-2, 79-92
15. Fiorucci, S.; Cipriani, S.; Mencarelli, A.; Renga, B.; Distrutti, E.; Baldelli, F. Counter-regulatory role of bile acid activated receptors in immunity and inflammation Curr. Mol. Med. 2010, 6, 579-595
16. Silveira, M. G.; Lindor, K. D. Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis Expert Opin. Pharmacother. 2014, 3, 365-372
17. Mudaliar, S.; Henry, R. R.; Sanyal, A. J.; Morrow, L.; Marschall, H. U.; Kipnes, M.; Adorini, L.; Sciacca, C. I.; Clopton, P.; Castelloe, E.; Dillon, P.; Pruzanski, M.; Shapiro, D. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease Gastroenterology 2013, 3, 574-82.e1
18. Ryan, K. K.; Tremaroli, V.; Clemmensen, C.; Kovatcheva-Datchary, P.; Myronovych, A.; Karns, R.; Wilson-Pérez, H. E.; Sandoval, D. A.; Kohli, R.; Bäckhed, F.; Seeley, R. J. FXR is a molecular target for the effects of vertical sleeve gastrectomy Nature 2014, 509, 183-188
19. Merk, D.; Steinhilber, D.; Schubert-Zsilavecz, M. Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators Future Med. Chem. 2012, 8, 1015-1036
20. Pellicciari, R.; Fiorucci, S.; Camaioni, E.; Clerici, C.; Costantino, G.; Maloney, P. R.; Morelli, A.; Parks, D. J.; Willson, T. M. 6alpha-Ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity J. Med. Chem. 2002, 17, 3569-3572
21. Maloney, P. R.; Parks, D. J.; Haffner, C. D.; Fivush, A. M.; Chandra, G.; Plunket, K. D.; Creech, K. L.; Moore, L. B.; Wilson, J. G.; Lewis, M. C.; Jones, S. A.; Willson, T. M. Identification of a Chemical Tool for the Orphan Nuclear Receptor FXR J. Med. Chem. 2000, 16, 2971-2974
22. Akwabi-Ameyaw, A.; Bass, J. Y.; Caldwell, R. D.; Caravella, J. A.; Chen, L.; Creech, K. L.; Deaton, D. N.; Jones, S. A.; Kaldor, I.; Liu, Y.; Madauss, K. P.; Marr, H. B.; McFadyen, R. B.; Miller, A. B.; Iii, F. N.; Parks, D. J.; Spearing, P. K.; Todd, D.; Williams, S. P.; Wisely, G. B. Conformationally constrained farnesoid X receptor (FXR) agonists: naphthoic acid-based analogs of GW 4064 Bioorg. Med. Chem. Lett. 2008, 15, 4339-4343
23. Chiang, P.; Thompson, D. C.; Ghosh, S.; Heitmeier, M. R. A formulation-enabled preclinical efficacy assessment of a farnesoid X receptor agonist, GW4064, in hamsters and cynomolgus monkeys J. Pharm. Sci. 2011, 11, 4722-4733
24. Howarth, D. L.; Law, S. H. W.; Law, J. M.; Mondon, J. A.; Kullman, S. W.; Hinton, D. E. Exposure to the synthetic FXR agonist GW4064 causes alterations in gene expression and sublethal hepatotoxicity in eleutheroembryo medaka (Oryzias latipes) Toxicol. Appl. Pharmacol. 2010, 1, 111-121
25. Flatt, B.; Martin, R.; Wang, T. L.; Mahaney, P.; Murphy, B.; Gu, X. H.; Foster, P.; Li, J.; Pircher, P.; Petrowski, M.; Schulman, I.; Westin, S.; Wrobel, J.; Yan, G.; Bischoff, E.; Daige, C.; Mohan, R. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR) J. Med. Chem. 2009, 4, 904-907
26. Singh, N.; Yadav, M.; Singh, A. K.; Kumar, H.; Dwivedi, S. K.; Mishra, J. S.; Gurjar, A.; Manhas, A.; Chandra, S.; Yadav, P. N.; Jagavelu, K.; Siddiqi, M. I.; Trivedi, A. K.; Chattopadhyay, N.; Sanyal, S. Synthetic FXR Agonist GW4064 Is a Modulator of Multiple G Protein-Coupled Receptors Mol. Endocrinol. 2014, 5, 659-673
27. Merk, D.; Steinhilber, D.; Schubert-Zsilavecz, M. Characterizing ligands for farnesoid X receptor - available in vitro test systems for farnesoid X receptor modulator development Expert Opin. Drug Discovery 2014, 1, 27-37
28. Merk, D.; Gabler, M.; Gomez, R. C.; Flesch, D.; Hanke, T.; Kaiser, A.; Lamers, C.; Werz, O.; Schneider, G.; Schubert-Zsilavecz, M. Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR) Bioorg. Med. Chem. 2014, 8, 2447-2460
29. Achenbach, J.; Gabler, M.; Steri, R.; Schubert-Zsilavecz, M.; Proschak, E. Identification of novel farnesoid X receptor modulators using a combined ligand- and structure-based virtual screening Med. Chem. Commun. 2013, 6, 920-924
30. Jin, T.; Kitahara, F.; Kamijo, S.; Yamamoto, Y. Copper-catalyzed synthesis of 5-substituted 1 H -tetrazoles via the [3 + 2] cycloaddition of nitriles and trimethylsilyl azide Tetrahedron Lett. 2008, 17, 2824-2827
31. Khalafi-Nezhad, A.; Parhami, A.; Soltani Rad, M. N.; Zarea, A. Efficient method for the direct preparation of amides from carboxylic acids using tosyl chloride under solvent-free conditions Tetrahedron Lett. 2005, 40, 6879-6882
32. Richter, H. G.; Benson, G. M.; Blum, D.; Chaput, E.; Feng, S.; Gardes, C.; Grether, U.; Hartman, P.; Kuhn, B.; Martin, R. E.; Plancher, J. M.; Rudolph, M. G.; Schuler, F.; Taylor, S.; Bleicher, K. H. Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia and diabetes Bioorg. Med. Chem. Lett. 2011, 1, 191-194
33. Akwabi-Ameyaw, A.; Caravella, J. A.; Chen, L.; Creech, K. L.; Deaton, D. N.; Madauss, K. P.; Marr, H. B.; Miller, A. B.; Navas, F., III; Parks, D. J.; Spearing, P. K.; Todd, D.; Williams, S. P.; Wisely, G. B. Conformationally constrained farnesoid X receptor (FXR) agonists: alternative replacements of the stilbene Bioorg. Med. Chem. Lett. 2011, 20, 6154-6160
34. Di Leva, F. S.; Festa, C.; DAmore, C.; De Marino, S.; Renga, B.; DAuria, M. V.; Novellino, E.; Limongelli, V.; Zampella, A.; Fiorucci, S. Binding Mechanism of the Farnesoid X Receptor Marine Antagonist Suvanine Reveals a Strategy To Forestall Drug Modulation on Nuclear Receptors. Design, Synthesis, and Biological Evaluation of Novel Ligands J. Med. Chem. 2013, 11, 4701-4717
35. De Gottardi, A.; Dumonceau, J. M.; Bruttin, F.; Vonlaufen, A.; Morard, I.; Spahr, L.; Rubbia-Brandt, L.; Frossard, J. L.; Dinjens, W. N.; Rabinovitch, P. S.; Hadengue, A. Expression of the bile acid receptor FXR in Barretts esophagus and enhancement of apoptosis by guggulsterone in vitro Mol. Cancer 2006, 5, 48
36. Capello, A.; Moons, L. M.; Van de Winkel, A.; Siersema, P. D.; van Dekken, H.; Kuipers, E. J.; Kusters, J. G. Bile Acid-Stimulated Expression of the Farnesoid X Receptor Enhances the Immune Response in Barrett Esophagus Am. J. Gastroenterol. 2008, 6, 1510-1516
37. Lee, J. Y.; Lee, K. T.; Lee, J. K.; Lee, K. H.; Jang, K. T.; Heo, J. S.; Choi, S. H.; Kim, Y.; Rhee, J. C. Farnesoid X receptor, overexpressed in pancreatic cancer with lymph node metastasis promotes cell migration and invasion Br J. Cancer 2011, 6, 1027-1037
38. De Gottardi, A.; Touri, F.; Maurer, C. A.; Perez, A.; Maurhofer, O.; Ventre, G.; Bentzen, C. L.; Niesor, E. J.; Dufour, J. F. The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer Dig. Dis. Sci. 2004, 6, 982-989
39. Journe, F.; Durbecq, V.; Chaboteaux, C.; Rouas, G.; Laurent, G.; Nonclercq, D.; Sotiriou, C.; Body, J. J.; Larsimont, D. Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast cancer from postmenopausal patients Breast Cancer Res. Treat. 2009, 3, 523-535
40. Silva, J.; Dasgupta, S.; Wang, G.; Krishnamurthy, K.; Ritter, E.; Bieberich, E. Lipids isolated from bone induce the migration of human breast cancer cells J. Lipid Res. 2006, 4, 724-733
41. Qi, Y.; Jiang, C.; Cheng, J.; Krausz, K. W.; Li, T.; Ferrell, J. M.; Gonzalez, F. J.; Chiang, J. Y. Bile acid signaling in lipid metabolism: metabolomic and lipidomic analysis of lipid and bile acid markers linked to anti-obesity and anti-diabetes in mice Biochim. Biophys. Acta 2014, 14, 1388-1981
42. Fiorucci, S.; Baldelli, F. Farnesoid X receptor agonists in biliary tract disease Curr. Opin. Gastroenterol. 2009, 3, 252-259
43. Steri, R.; Achenbach, J.; Steinhilber, D.; Schubert-Zsilavecz, M.; Proschak, E. Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity Biochem. Pharmacol. 2012, 12, 1674-1681
44. Ananthanarayanan, M. Human Bile Salt Export Pump Promoter Is Transactivated by the Farnesoid X Receptor/Bile Acid Receptor J. Biol. Chem. 2001, 31, 28857-28865
45. Seuter, S.; Väisänen, S.; Rådmark, O.; Carlberg, C.; Steinhilber, D. Functional characterization of vitamin D responding regions in the human 5-lipoxygenase gene Biochim. Biophys. Acta 2007, 7, 864-872
46. Rau, O.; Wurglics, M.; Paulke, A.; Zitzkowski, J.; Meindl, N.; Bock, A.; Dingermann, T.; Abdel-Tawab, M.; Schubert-Zsilavecz, M. Carnosic acid and carnosol, phenolic diterpene compounds of the labiate herbs rosemary and sage, are activators of the human peroxisome proliferator-activated receptor gamma Planta Med. 2006, 10, 881-887